Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund

Updated: Nov 14, 2024

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program, QXL138AM.

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF's Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM

Recent Posts

See All

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma

Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Nammi Therapeutics Featured in Los Angeles Business Journal

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...

Amgen and BioLabs LA Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket

Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...

Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund

Recent Posts

留言